Behavioral Research Specialists LLC

1. ITI, Inc. $599,711 58 payments
2. Janssen Research & Development, LLC $255,223 16 payments
3. ACADIA Pharmaceuticals Inc $247,489 21 payments
4. Sage Therapeutics, Inc. $190,941 9 payments
5. Allergan Inc. $171,057 27 payments
6. Boehringer Ingelheim Pharmaceuticals, Inc. $132,970 5 payments
7. Otsuka Pharmaceutical Development & Commercialization, Inc. $108,652 7 payments
8. Neurocrine Biosciences, Inc. $102,029 44 payments
9. Jazz Pharmaceuticals Inc. $71,608 6 payments
10. Supernus Pharmaceuticals, Inc. $53,377 10 payments

1. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone As Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder $261,397 19 payments
2. An Open-Label Multicenter Trial to Assess the Safety and Tolerability of Lumateperone As Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder $200,795 22 payments
3. Acp-103-059 $181,011 11 payments
4. A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment $93,690 9 payments
5. A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an $92,584 5 payments
6. A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Sage-217 in the Treatment of Adult Subjects With Major Depressive Disorder $89,356 3 payments
7. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $72,863 1 payment
8. PoCC study in patients with PTSD $72,663 2 payments
9. A Multicenter Phase 2 12-Week Double-Blind Placebo-Controlled Randomized Parallel-Group Study of Jzp150 for the Treatment of Posttraumatic Stress Disorder $71,608 6 payments
10. Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Or Most Recent Episode Is Manic $69,530 6 payments

1. Patient care $23,640 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.